Neuropace Inc Stock Price, News & Analysis

MOUNTAIN VIEW, Calif., Dec. 21, 2022 - NeuroPace (Nasdaq: NPCE) announced participation in the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12^th, 2023, at 9:00 a.m. Pacific Time. A live webcast and archived recording of their presentation will be accessible on the company’s investor website. NeuroPace is dedicated to improving the lives of people with epilepsy through its innovative RNS System, the first brain-responsive platform for real-time treatment at the seizure source, potentially enhancing care for patients with drug-resistant epilepsy.

NeuroPace, Inc. (NASDAQ: NPCE) has commenced a feasibility study involving the treatment of the first patient with Lennox-Gastaut Syndrome (LGS) using its RNS^® System. This system, previously effective for focal onset seizures, aims to evaluate brain-responsive neurostimulation for LGS, a severe epilepsy type. Funded by a $9.3 million NIH grant, the study spans six sites enrolling 20 patients. Current treatments show limited efficacy, highlighting the urgent need for innovative interventions in managing LGS.

NeuroPace, Inc. (Nasdaq: NPCE) reported third-quarter 2022 financial results, achieving $11.2 million in total revenue, an 8% increase year-over-year. Initial implant revenue reached $9.2 million, up 18% from the prior year. Despite a decline in replacement implant revenue, the company initiated the distribution of DIXI Medical’s stereo EEG products. Operating expenses rose to $18.2 million, leading to a net loss of $11.8 million. The company updated its 2022 revenue guidance to $44.5 million to $45.5 million, reflecting positive growth expectations.

NeuroPace, Inc. (NPCE), a medical device company, will participate in the 4th Annual Wolfe Research Healthcare Conference on November 16, 2022, at 2:40 p.m. Eastern Time. The event will feature a presentation from company management, and a live webcast will be accessible on the company's website. NeuroPace focuses on innovative treatments for epilepsy, particularly through its RNS System, which provides personalized, real-time therapy to reduce seizures in drug-resistant epilepsy patients. The webcast will be available for replay for at least 90 days post-event.

NeuroPace, Inc. (Nasdaq: NPCE) will report its Q3 2022 financial results after market close on November 8, 2022. A conference call will follow at 1:30 PM PT / 4:30 PM ET, allowing investors to listen live or via archived webcast on their website. NeuroPace focuses on enhancing the quality of life for those with epilepsy using its RNS System, a brain-responsive treatment platform aimed at reducing seizures, particularly for drug-resistant epilepsy patients. This innovation may offer a more personalized care approach for various brain disorders.

NeuroPace, Inc. (NASDAQ: NPCE) has announced the initiation of the NAUTILUS clinical study, evaluating the RNS® System for treating drug-resistant idiopathic generalized epilepsy (IGE) in patients aged 12 and older. The first patient was treated at Vanderbilt Health in Nashville, TN. This pivotal study aims to demonstrate the safety and effectiveness of the RNS System, which utilizes brain-responsive neuromodulation. The RNS System, already FDA-approved for focal epilepsy, has received Breakthrough Device Designation for IGE treatment, highlighting its potential to fill a significant unmet medical need.

MOUNTAIN VIEW, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. Management will present on September 13 at 12:20 p.m. Eastern Time. The event will be accessible via a live webcast and archived for at least 90 days on the company’s website.

NeuroPace focuses on transforming the lives of epilepsy patients with its RNS System, the first brain-responsive platform for real-time treatment, aiming to improve outcomes for those with drug-resistant epilepsy.

NeuroPace (Nasdaq: NPCE) reported Q2 2022 revenues of $10.2 million, down from $12.6 million year-over-year. The initial implant revenue was $8.0 million, a decrease from $9.2 million, primarily due to reduced patient volumes in Epilepsy Monitoring Units (EMUs) and COVID-19 cancellations. The net loss widened to $12.7 million from $8.5 million in the previous year. Guidance for 2022 forecasts total revenues between $43 million and $45 million, driven by new partnerships and an expanded sales team.

NeuroPace (Nasdaq: NPCE) has entered a commercialization agreement with DIXI Medical to exclusively market and sell its diagnostic electrodes for epilepsy in the U.S. This agreement takes effect on October 1, 2022. NeuroPace will promote stereoelectroencephalography (SEEG) electrodes, crucial for pinpointing seizure sources in patients with drug-resistant epilepsy. DIXI will support physicians with education and outreach, receiving an upfront payment and subsequent payments in 2023 and 2024. This partnership aims to enhance treatment options for epilepsy patients through combined expertise.